These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18484428)

  • 1. Effect of oxybutynin on exercise-induced sweating in healthy individuals.
    van Houte M; Harmsze AM; Deneer VH; Tupker RA
    J Dermatolog Treat; 2008; 19(2):101-4. PubMed ID: 18484428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exercise-induced sweating in healthy subjects as a model to predict a drug's sweat-reducing properties in hyperhydrosis: a prospective, placebo-controlled, double-blind study.
    Harmsze AM; Houte Mv; Deneer VH; Tupker RA
    Acta Derm Venereol; 2008; 88(2):108-12. PubMed ID: 18311434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
    Wolosker N; de Campos JR; Kauffman P; Puech-Leão P
    J Vasc Surg; 2012 Jun; 55(6):1696-700. PubMed ID: 22341836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
    Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
    J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of oxybutynin for treating axillary hyperhidrosis.
    Wolosker N; de Campos JR; Kauffman P; Neves S; Munia MA; BiscegliJatene F; Puech-Leão P
    Ann Vasc Surg; 2011 Nov; 25(8):1057-62. PubMed ID: 22023940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients.
    Kim WO; Kil HK; Yoon KB; Yoo JH
    Acta Derm Venereol; 2010 May; 90(3):291-3. PubMed ID: 20526549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxybutynin: dry days for patients with hyperhidrosis.
    Mijnhout GS; Kloosterman H; Simsek S; Strack van Schijndel RJ; Netelenbos JC
    Neth J Med; 2006 Oct; 64(9):326-8. PubMed ID: 17057269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
    Pariser DM; Krishnaraja J; Tremblay TM; Rubison RM; Love TW; McGraw BF
    J Drugs Dermatol; 2017 Feb; 16(2):127-132. PubMed ID: 28300854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V;
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis.
    Wolosker N; Krutman M; Teivelis MP; Campbell TP; Kauffman P; de Campos JR; Puech-Leão P
    Ann Vasc Surg; 2014 May; 28(4):970-6. PubMed ID: 24333527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis.
    Wolosker N; Teivelis MP; Krutman M; de Paula RP; Kauffman P; de Campos JR; Puech-Leão P
    Ann Vasc Surg; 2014 Jul; 28(5):1106-12. PubMed ID: 24512855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old.
    Wolosker N; Schvartsman C; Krutman M; Campbell TP; Kauffman P; de Campos JR; Puech-Leão P
    Pediatr Dermatol; 2014; 31(1):48-53. PubMed ID: 23627681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy.
    Costa Ada S; Leão LE; Succi JE; Perfeito JA; Filho Castelo A; Rymkiewicz E; Filho Aurelio Marchetti M
    Clinics (Sao Paulo); 2014 Feb; 69(2):101-5. PubMed ID: 24519200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
    Reiz JL; Salem P; Darke AC
    J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.
    Schollhammer M; Brenaut E; Menard-Andivot N; Pillette-Delarue M; Zagnoli A; Chassain-Le Lay M; Sassolas B; Jouan N; Le Ru Y; Abasq-Thomas C; Greco M; Penven K; Roguedas-Contios AM; Dupré-Goetghebeur D; Gouedard C; Misery L; Le Gal G
    Br J Dermatol; 2015 Nov; 173(5):1163-8. PubMed ID: 26114588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.
    Teivelis MP; Wolosker N; Krutman M; Kauffman P; Campos JR; Puech-Leão P
    Clinics (Sao Paulo); 2014 Sep; 69(9):608-14. PubMed ID: 25318092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eccrine sweat response in children with asthma.
    Oflu A; Soyer OU; Tuncer A; Sackesen C; Kalayci O
    Allergy; 2010 May; 65(5):645-8. PubMed ID: 19886927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of oxybutynin for treating plantar hyperhidrosis.
    Wolosker N; de Campos JR; Kauffman P; Yazbek G; Neves S; Puech-Leao P
    Int J Dermatol; 2013 May; 52(5):620-3. PubMed ID: 23590378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
    Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
    J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.